Redirecting innovation in U.S. health care : : options to decrease spending and increase value / / Steven Garber [and six others].
New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits, and (...
Saved in:
VerfasserIn: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | Santa Monica, California : : RAND Corporation,, 2014. ©2014 |
Year of Publication: | 2014 |
Language: | English |
Physical Description: | 1 online resource (135 p.) |
Notes: | Description based upon print version of record. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993628388204498 |
---|---|
ctrlnum |
(CKB)3710000000108683 (EBL)1684540 (SSID)ssj0001216878 (PQKBManifestationID)11836996 (PQKBTitleCode)TC0001216878 (PQKBWorkID)11197744 (PQKB)10803063 (Au-PeEL)EBL1684540 (CaPaEBR)ebr10867874 (OCoLC)879551018 (MiAaPQ)EBC1684540 (EXLCZ)993710000000108683 |
collection |
bib_alma |
record_format |
marc |
spelling |
Garber, Steven, 1950- author. Redirecting innovation in U.S. health care : options to decrease spending and increase value / Steven Garber [and six others]. Santa Monica, California : RAND Corporation, 2014. ©2014 1 online resource (135 p.) text txt computer c online resource cr Description based upon print version of record. Cover; Title Page; Copyright; Preface; Contents; Figures; Summary; Acknowledgments; Abbreviations; Chapter One: Introduction; Project Goals; What Determines Value for Health Care Products?; Chapter Two: The Context for Medical Product Innovation; Three Stages of Innovation; Primary Actors in Inventing Medical Products; Drug and Device Companies; HIT Companies; Goals of Medical Product Inventors; Private Investors; Financial Incentives of Medical Product Inventors; Influencers of Medical Product Invention; National Institutes of Health; U.S. Food and Drug Administration U.S. Patent and Trademark Office Office of the National Coordinator for Health Information Technology; Primary Actor and Influencers in Approval of Medical Technologies; Primary Actors in Adoption of Medical Products; Physicians; Hospitals; Influencers of Providers; Summary: Context for Medical Product Innovation; Chapter Three: Methods; Literature Reviews; Technical Expert Panel; Expert Interviews; Case Studies; Policy Options; Chapter Four: Analysis; Lack of Basic Scientific Knowledge; Lack of an Adequate Knowledge Base Can Hinder Product Inventors Sources of Financial Support for Increasing Basic Scientific Knowledge Federal Funding Is Critical to Expanding the Basic Scientific Base; Case Study Summary: Haemophilus influenzae Type b (Hib) Vaccine; How Scientific Uncertainty Affects Medical Product Invention; Costs and Risks of FDA Approval; Could the FDA Ensure Safety with Quicker and Less Costly Processes?; Delays Entail Both Health and Financial Costs; Case Study Summary: A Cardiovascular Polypill; Unpredictability and Ineffective Communication Complicate the Approval Process; FDA Caution May Be a Root Cause of Regulatory Delay Case Study Summary: Avastin for Metastatic Breast Cancer Regulatory Risk Figures Prominently in Investment and Invention Decisions; How Regulatory Uncertainty Affects Investment and Invention; Limited Rewards for Medical Products That Could Lower Spending; Many Patients and Providers Are Fairly Insensitive to Prices; Generous Health Insurance Tends to Reduce Consumers' Sensitivity to Price; Fee-for-Service Payment Also Tends to Reduce Price Sensitivity; Lack of Price Transparency Also Reduces Price Sensitivity; Medicare Is Not Allowed to Consider Costs in Coverage and Reimbursement Decisions Limited Time Horizons and Fragmented Decision making Case Study Summary: Electronic Health Records; Inadequate Rewards for Products That Decrease Spending; Implications for Inventors and Investors; Treatment Creep; Case Study Summary: Implantable Cardioverter-Defibrillator; Manufacturers Can Promote Low-Value Use; Case Study Summary: Prostate-Specific Antigen; Defensive Medicine Is a Form of Treatment Creep; Off-Label Use of Medical Products Is Widespread, but Health Effects Are Unknown; It Is Difficult to Control Undesirable Instances of Off-Label Use Treatment Creep Can Substantially Affect Incentives for Innovators New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits, and (2) ensure that new medical products that increase spending are accompanied by health benefits that are worth the spending increases. English Includes bibliographical references. Description based on online resource; title from PDF title page (ebrary, viewed May 15, 2014). Medical care United States. Medical care, Cost of United States. Medical innovations. Garber, Steven, author. 0-8330-8546-8 |
language |
English |
format |
eBook |
author |
Garber, Steven, 1950- Garber, Steven, |
spellingShingle |
Garber, Steven, 1950- Garber, Steven, Redirecting innovation in U.S. health care : options to decrease spending and increase value / Cover; Title Page; Copyright; Preface; Contents; Figures; Summary; Acknowledgments; Abbreviations; Chapter One: Introduction; Project Goals; What Determines Value for Health Care Products?; Chapter Two: The Context for Medical Product Innovation; Three Stages of Innovation; Primary Actors in Inventing Medical Products; Drug and Device Companies; HIT Companies; Goals of Medical Product Inventors; Private Investors; Financial Incentives of Medical Product Inventors; Influencers of Medical Product Invention; National Institutes of Health; U.S. Food and Drug Administration U.S. Patent and Trademark Office Office of the National Coordinator for Health Information Technology; Primary Actor and Influencers in Approval of Medical Technologies; Primary Actors in Adoption of Medical Products; Physicians; Hospitals; Influencers of Providers; Summary: Context for Medical Product Innovation; Chapter Three: Methods; Literature Reviews; Technical Expert Panel; Expert Interviews; Case Studies; Policy Options; Chapter Four: Analysis; Lack of Basic Scientific Knowledge; Lack of an Adequate Knowledge Base Can Hinder Product Inventors Sources of Financial Support for Increasing Basic Scientific Knowledge Federal Funding Is Critical to Expanding the Basic Scientific Base; Case Study Summary: Haemophilus influenzae Type b (Hib) Vaccine; How Scientific Uncertainty Affects Medical Product Invention; Costs and Risks of FDA Approval; Could the FDA Ensure Safety with Quicker and Less Costly Processes?; Delays Entail Both Health and Financial Costs; Case Study Summary: A Cardiovascular Polypill; Unpredictability and Ineffective Communication Complicate the Approval Process; FDA Caution May Be a Root Cause of Regulatory Delay Case Study Summary: Avastin for Metastatic Breast Cancer Regulatory Risk Figures Prominently in Investment and Invention Decisions; How Regulatory Uncertainty Affects Investment and Invention; Limited Rewards for Medical Products That Could Lower Spending; Many Patients and Providers Are Fairly Insensitive to Prices; Generous Health Insurance Tends to Reduce Consumers' Sensitivity to Price; Fee-for-Service Payment Also Tends to Reduce Price Sensitivity; Lack of Price Transparency Also Reduces Price Sensitivity; Medicare Is Not Allowed to Consider Costs in Coverage and Reimbursement Decisions Limited Time Horizons and Fragmented Decision making Case Study Summary: Electronic Health Records; Inadequate Rewards for Products That Decrease Spending; Implications for Inventors and Investors; Treatment Creep; Case Study Summary: Implantable Cardioverter-Defibrillator; Manufacturers Can Promote Low-Value Use; Case Study Summary: Prostate-Specific Antigen; Defensive Medicine Is a Form of Treatment Creep; Off-Label Use of Medical Products Is Widespread, but Health Effects Are Unknown; It Is Difficult to Control Undesirable Instances of Off-Label Use Treatment Creep Can Substantially Affect Incentives for Innovators |
author_facet |
Garber, Steven, 1950- Garber, Steven, Garber, Steven, |
author_variant |
s g sg s g sg |
author_role |
VerfasserIn VerfasserIn |
author2 |
Garber, Steven, |
author2_role |
TeilnehmendeR |
author_sort |
Garber, Steven, 1950- |
title |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / |
title_sub |
options to decrease spending and increase value / |
title_full |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / Steven Garber [and six others]. |
title_fullStr |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / Steven Garber [and six others]. |
title_full_unstemmed |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / Steven Garber [and six others]. |
title_auth |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / |
title_new |
Redirecting innovation in U.S. health care : |
title_sort |
redirecting innovation in u.s. health care : options to decrease spending and increase value / |
publisher |
RAND Corporation, |
publishDate |
2014 |
physical |
1 online resource (135 p.) |
contents |
Cover; Title Page; Copyright; Preface; Contents; Figures; Summary; Acknowledgments; Abbreviations; Chapter One: Introduction; Project Goals; What Determines Value for Health Care Products?; Chapter Two: The Context for Medical Product Innovation; Three Stages of Innovation; Primary Actors in Inventing Medical Products; Drug and Device Companies; HIT Companies; Goals of Medical Product Inventors; Private Investors; Financial Incentives of Medical Product Inventors; Influencers of Medical Product Invention; National Institutes of Health; U.S. Food and Drug Administration U.S. Patent and Trademark Office Office of the National Coordinator for Health Information Technology; Primary Actor and Influencers in Approval of Medical Technologies; Primary Actors in Adoption of Medical Products; Physicians; Hospitals; Influencers of Providers; Summary: Context for Medical Product Innovation; Chapter Three: Methods; Literature Reviews; Technical Expert Panel; Expert Interviews; Case Studies; Policy Options; Chapter Four: Analysis; Lack of Basic Scientific Knowledge; Lack of an Adequate Knowledge Base Can Hinder Product Inventors Sources of Financial Support for Increasing Basic Scientific Knowledge Federal Funding Is Critical to Expanding the Basic Scientific Base; Case Study Summary: Haemophilus influenzae Type b (Hib) Vaccine; How Scientific Uncertainty Affects Medical Product Invention; Costs and Risks of FDA Approval; Could the FDA Ensure Safety with Quicker and Less Costly Processes?; Delays Entail Both Health and Financial Costs; Case Study Summary: A Cardiovascular Polypill; Unpredictability and Ineffective Communication Complicate the Approval Process; FDA Caution May Be a Root Cause of Regulatory Delay Case Study Summary: Avastin for Metastatic Breast Cancer Regulatory Risk Figures Prominently in Investment and Invention Decisions; How Regulatory Uncertainty Affects Investment and Invention; Limited Rewards for Medical Products That Could Lower Spending; Many Patients and Providers Are Fairly Insensitive to Prices; Generous Health Insurance Tends to Reduce Consumers' Sensitivity to Price; Fee-for-Service Payment Also Tends to Reduce Price Sensitivity; Lack of Price Transparency Also Reduces Price Sensitivity; Medicare Is Not Allowed to Consider Costs in Coverage and Reimbursement Decisions Limited Time Horizons and Fragmented Decision making Case Study Summary: Electronic Health Records; Inadequate Rewards for Products That Decrease Spending; Implications for Inventors and Investors; Treatment Creep; Case Study Summary: Implantable Cardioverter-Defibrillator; Manufacturers Can Promote Low-Value Use; Case Study Summary: Prostate-Specific Antigen; Defensive Medicine Is a Form of Treatment Creep; Off-Label Use of Medical Products Is Widespread, but Health Effects Are Unknown; It Is Difficult to Control Undesirable Instances of Off-Label Use Treatment Creep Can Substantially Affect Incentives for Innovators |
isbn |
0-8330-8549-2 0-8330-8547-6 0-8330-8546-8 |
callnumber-first |
R - Medicine |
callnumber-subject |
RA - Public Medicine |
callnumber-label |
RA395 |
callnumber-sort |
RA 3395 A3 R435 42014 |
geographic_facet |
United States. |
illustrated |
Illustrated |
dewey-hundreds |
300 - Social sciences |
dewey-tens |
360 - Social problems & social services |
dewey-ones |
362 - Social welfare problems & services |
dewey-full |
362.10973 |
dewey-sort |
3362.10973 |
dewey-raw |
362.10973 |
dewey-search |
362.10973 |
oclc_num |
879551018 |
work_keys_str_mv |
AT garbersteven redirectinginnovationinushealthcareoptionstodecreasespendingandincreasevalue |
status_str |
n |
ids_txt_mv |
(CKB)3710000000108683 (EBL)1684540 (SSID)ssj0001216878 (PQKBManifestationID)11836996 (PQKBTitleCode)TC0001216878 (PQKBWorkID)11197744 (PQKB)10803063 (Au-PeEL)EBL1684540 (CaPaEBR)ebr10867874 (OCoLC)879551018 (MiAaPQ)EBC1684540 (EXLCZ)993710000000108683 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Redirecting innovation in U.S. health care : options to decrease spending and increase value / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796653687290986496 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05219nam a2200601 i 4500</leader><controlfield tag="001">993628388204498</controlfield><controlfield tag="005">20231108003917.0</controlfield><controlfield tag="006">m o d | </controlfield><controlfield tag="007">cr#-n---------</controlfield><controlfield tag="008">140517t20142014caua ob 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0-8330-8549-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0-8330-8547-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000108683</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBL)1684540</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SSID)ssj0001216878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBManifestationID)11836996</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBTitleCode)TC0001216878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBWorkID)11197744</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKB)10803063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(Au-PeEL)EBL1684540</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaPaEBR)ebr10867874</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)879551018</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(MiAaPQ)EBC1684540</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000108683</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">MiAaPQ</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">MiAaPQ</subfield><subfield code="d">MiAaPQ</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RA395.A3</subfield><subfield code="b">.R435 2014</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.10973</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garber, Steven,</subfield><subfield code="d">1950-</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Redirecting innovation in U.S. health care :</subfield><subfield code="b">options to decrease spending and increase value /</subfield><subfield code="c">Steven Garber [and six others].</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Santa Monica, California :</subfield><subfield code="b">RAND Corporation,</subfield><subfield code="c">2014.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (135 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based upon print version of record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover; Title Page; Copyright; Preface; Contents; Figures; Summary; Acknowledgments; Abbreviations; Chapter One: Introduction; Project Goals; What Determines Value for Health Care Products?; Chapter Two: The Context for Medical Product Innovation; Three Stages of Innovation; Primary Actors in Inventing Medical Products; Drug and Device Companies; HIT Companies; Goals of Medical Product Inventors; Private Investors; Financial Incentives of Medical Product Inventors; Influencers of Medical Product Invention; National Institutes of Health; U.S. Food and Drug Administration</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">U.S. Patent and Trademark Office Office of the National Coordinator for Health Information Technology; Primary Actor and Influencers in Approval of Medical Technologies; Primary Actors in Adoption of Medical Products; Physicians; Hospitals; Influencers of Providers; Summary: Context for Medical Product Innovation; Chapter Three: Methods; Literature Reviews; Technical Expert Panel; Expert Interviews; Case Studies; Policy Options; Chapter Four: Analysis; Lack of Basic Scientific Knowledge; Lack of an Adequate Knowledge Base Can Hinder Product Inventors</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Sources of Financial Support for Increasing Basic Scientific Knowledge Federal Funding Is Critical to Expanding the Basic Scientific Base; Case Study Summary: Haemophilus influenzae Type b (Hib) Vaccine; How Scientific Uncertainty Affects Medical Product Invention; Costs and Risks of FDA Approval; Could the FDA Ensure Safety with Quicker and Less Costly Processes?; Delays Entail Both Health and Financial Costs; Case Study Summary: A Cardiovascular Polypill; Unpredictability and Ineffective Communication Complicate the Approval Process; FDA Caution May Be a Root Cause of Regulatory Delay</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Case Study Summary: Avastin for Metastatic Breast Cancer Regulatory Risk Figures Prominently in Investment and Invention Decisions; How Regulatory Uncertainty Affects Investment and Invention; Limited Rewards for Medical Products That Could Lower Spending; Many Patients and Providers Are Fairly Insensitive to Prices; Generous Health Insurance Tends to Reduce Consumers' Sensitivity to Price; Fee-for-Service Payment Also Tends to Reduce Price Sensitivity; Lack of Price Transparency Also Reduces Price Sensitivity; Medicare Is Not Allowed to Consider Costs in Coverage and Reimbursement Decisions</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Limited Time Horizons and Fragmented Decision making Case Study Summary: Electronic Health Records; Inadequate Rewards for Products That Decrease Spending; Implications for Inventors and Investors; Treatment Creep; Case Study Summary: Implantable Cardioverter-Defibrillator; Manufacturers Can Promote Low-Value Use; Case Study Summary: Prostate-Specific Antigen; Defensive Medicine Is a Form of Treatment Creep; Off-Label Use of Medical Products Is Widespread, but Health Effects Are Unknown; It Is Difficult to Control Undesirable Instances of Off-Label Use</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Treatment Creep Can Substantially Affect Incentives for Innovators</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits, and (2) ensure that new medical products that increase spending are accompanied by health benefits that are worth the spending increases.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (ebrary, viewed May 15, 2014).</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care, Cost of</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical innovations.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garber, Steven,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">0-8330-8546-8</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-11-09 11:41:47 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2014-05-03 20:46:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5350475810004498&Force_direct=true</subfield><subfield code="Z">5350475810004498</subfield><subfield code="b">Available</subfield><subfield code="8">5350475810004498</subfield></datafield></record></collection> |